Coolproteomics.com|It’s all about proteins, isn’t it?

Imagine if you could immobilize membrane proteins in their native state to a microfluidic surface?

That’s what Nanoxis’ microfluidic LPI™ FlowCell can do. This is one of those products that few proteomic researchers know about, but once publications appear - and they are coming - this company’s products will be in demand.

So why focus a company and its technology on membrane proteins? About 70% of all major drugs sold today target membrane proteins linked to diseases such as diabetes, hypertension and cancer. However, a small fraction of all membrane proteins have yet to be well characterized - take GPCRs for example - only 10% have been identified. Any progress in our ability to work with membrane proteins is therefore likely to, eventually, help people with diseases receive better treatment. It is predicted that fully two thirds of all anticipated new drugs will need to act on membrane proteins; that’s a very powerful story for building a company and new technology.

Nanoxis (www.nanoxis.com), founded in 2002, is a small company located in the city of Gothenburg… a region with a population of about one million people and known for some of the best restaurants in Europe. The folks from Nanoxis have exhibited at several symposiums and trade shows in the US and all over the globe. Look for them at this year’s Protein Society meeting in San Diego (booth 512) and ask for Tynde Sandor, Nanoxis’ worldwide sales manager.

If you are working on membrane proteins and would like more information on Nanoxis’ and others’ technologies drop me a note… I’d love to cross paths.